PURA and myelodysplastic syndrome: In addition, deletions or mutations in PURA have now been implicated in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and PURA syndrome characterized by neonatal hypotonia, respiratory compromise, feeding difficulties, severe intellectual disability and epilepsy [17,18,19,20].